AC Immune Q2 2025 Earnings Report

AC Immune EPS Results

• Actual EPS: -$0.25
• Consensus EPS: -$0.20
• Beat/Miss: Missed by -$0.05
• One Year Ago EPS: N/A

AC Immune Revenue Results

• Actual Revenue: $1.65 million
• Expected Revenue: $1.98 million
• Beat/Miss: Missed by -$333.00 thousand
• YoY Revenue Growth: N/A

AC Immune Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 5, 2025
• Conference Call Time: 12:00AM ET

AC Immune (NASDAQ:ACIU) AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development. Its SupraAntigen™ platform is designed to generate active vaccines that elicit a targeted immune response against disease-associated proteins, while its Morphomer™ platform discovers small molecules that bind misfolded proteins and inhibit their toxic aggregation. Among the company’s leading assets are anti-tau vaccine candidates in mid-stage clinical trials and small-molecule inhibitors aimed at disrupting toxic oligomer formation.

AC Immune maintains collaborations and strategic partnerships with major pharmaceutical firms to accelerate development and expand global reach. Notable alliances include research agreements with Janssen Pharmaceuticals and UCB to co-develop immunotherapies for Alzheimer’s and Parkinson’s diseases, as well as partnerships with Eli Lilly and Genentech focused on diagnostic imaging agents. These collaborations strengthen AC Immune’s ability to advance its pipeline while accessing broader regulatory and commercialization expertise.

Under the leadership of CEO Dr. Andrea Pfeifer, who co-founded the company and has guided its growth since inception, AC Immune continues to invest in innovative approaches to neurodegeneration. The company’s integrated research and development model, combining both therapeutic and diagnostic strategies, aims to deliver precision solutions that address unmet medical needs in aging populations across North America, Europe and Asia.